T. Rowe Price Associates
FBRX icon

T. Rowe Price Associates’s Forte Biosciences FBRX Stock Holding History

T. Rowe Price Associates’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$338K Buy
+15,900
New +$377K ﹤0.01% 2804
2019
Q3 		– Sell
-1,339
Closed -$3.35M – 2529
2019
Q2 		$3.35M Sell
1,339
-341
-20% -$1.01M ﹤0.01% 1453
2019
Q1 		$6.85M Sell
1,680
-181
-10% -$699K ﹤0.01% 1365
2018
Q4 		$5.73M Buy
1,861
+381
+26% +$1.64M ﹤0.01% 1388
2018
Q3 		$8.65M Buy
1,480
+633
+75% +$2.41M ﹤0.01% 1398
2018
Q2 		$2.97M Sell
847
-1,261
-60% -$4.62M ﹤0.01% 1512
2018
Q1 		$9.37M Sell
2,108
-40
-2% -$185K ﹤0.01% 1348
2017
Q4 		$8.26M Buy
2,148
+191
+10% +$762K ﹤0.01% 1367
2017
Q3 		$9.14M Buy
1,957
+478
+32% +$2.13M ﹤0.01% 1348
2017
Q2 		$6.67M Buy
+1,479
New +$8.32M ﹤0.01% 1377

Other funds holding FBRX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return

T. Rowe Price Associates's FBRX Position: Q2 2026 in Review

T. Rowe Price Associates opened a new position in Forte Biosciences (FBRX) in Q2 2026: 15,900 shares worth $338K. The stake represents ﹤0.01% of the portfolio and ranks #2804 among its holdings. This is a return to the name: T. Rowe Price Associates previously reported a position in FBRX as recently as Q2 2019.

T. Rowe Price Associates first reported a position in FBRX in Q2 2017 and has held it in 10 quarters since. The position peaked at $9.37M in Q1 2018. 57 funds tracked by Wall St. Rank hold FBRX as of Q2 2026.

  • T. Rowe Price Associates held 15,900 shares of Forte Biosciences worth $338K as of Q2 2026.
  • Forte Biosciences was a new T. Rowe Price Associates position in Q2 2026.
  • Forte Biosciences made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2804 holding.
  • T. Rowe Price Associates first reported a position in Forte Biosciences in Q2 2017 and has held it in 10 quarters since.
  • T. Rowe Price Associates's Forte Biosciences position peaked at $9.37M in Q1 2018.
  • 57 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.